CSL Behring
CSL Behring is a global biotechnology company that develops and manufactures plasma-derived and recombinant therapies to treat rare and serious medical conditions, including bleeding disorders, immune deficiencies, and respiratory diseases. It serves hospitals, clinics, and specialty pharmacies worldwide, generating revenue through the sale of its biotherapeutic products and related services. CSL Behring operates as a subsidiary of CSL Limited, focusing on research, development, and large-scale production of specialty biologics.
- Revenue
- $12.0B
- Employees
- 30,000
- Founded
- 1904
- Headquarters
- King of Prussia, United States of America
What 23 Arbolus experts think of CSL Behring
The NPS distribution for CSL Behring is weighted toward the positive, with multiple experts rating 8–10 and only one recording a '0' (outlier). Most experts with renewal intent are committed to continuing, particularly those in mature or multi-year implementations. Stickiness is high among established users, with a minority in the offboarding stage. Key themes from expert feedback include product reliability, integration, and dependable support. Negative feedback centers on budget constraints and competitive platform threats. Overall Customer Sentiment: Positive
Who reviewed CSL Behring
- C-Suite 72% (17)
- Director 22% (5)
- Manager 6% (1)
Employer names and spend open in the full report, along with the other 20 customers.
Everything 23 customers told us about CSL Behring.
Employer names, spend, renewal intent and every written answer behind the numbers on this page.
Sentiment
40 Net Promoter Score, from 22 scored reviews- Promoters 12
- Passives 7
- Detractors 3
Cumulative NPS by month
+0 over 6 months- Apr 8
- Jun 8
- Jul 8
- Aug 9
- Sep 8
- Oct 8
Net Promoter Score across 2 reviews, accumulated up to each month. Category median 31 across 2 companies.
Praised
- Workflow Integration and Reliability
- Stable Budget Allocation
- Customer Support Strength
- Educational and Operational Support
Criticised
- Competitive Platform Strength
- Reimbursement Environment Changes
- Supply Chain Disruptions
- Potential for Competitive Displacement
What customers say
Renewal intent
Plan to renew 63%Plan to renew, by seniority
- 73% 11 answers
- 25% 4 answers
- 75% 4 answers
- 8.7/10 Average score from customers who will renew
- 7.5/10 Average score from undecided customers
- 6.3/10 Average score from customers not renewing
Top alternatives
Most weighed by CSL Behring customers
Report
For people who use CSL Behring
Do you use CSL Behring at work?
Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.
- 23 customers of CSL Behring have already contributed
Takes a few minutes. Your identity stays anonymous.